Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Corporate Update
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a pioneering clinical-stage biotechnology company, has announced its financial results for the year ended December 31, 2024, alongside a significant corporate update. The company remains focused on advancing adeno-associated virus (AAV)-based gene therapies aimed at treating severe monogenic diseases of the central nervous system (CNS), with an emphasis on its lead candidate, TSHA-102, for Rett syndrome.
1. Progress in TSHA-102 Clinical Trials
In his remarks, Sean P. Nolan, Chairman and CEO of Taysha, expressed optimism regarding the progress of the TSHA-102 clinical program. "We are pleased with the pace at which our TSHA-102 clinical program is advancing across a broad range of ages and stages of patients with Rett syndrome," Nolan stated. The company has completed dosing for 10 patients in Part A of its REVEAL trials, which include both adolescent/adult and pediatric cohorts.
Positive Safety Profile
The preliminary data from the REVEAL trials reveal that TSHA-102 has been generally well tolerated among the cohort, with no treatment-related serious adverse events or dose-limiting toxicities reported. The high dose cohort included six patients, while the low dose cohort comprised four patients. This data is pivotal as Taysha moves toward the next phase in its clinical development, aiming to solidify the regulatory path with the U.S. Food and Drug Administration (FDA).
2. Corporate Highlights
- Completion of Dosing: The dosing of 10 patients in Part A of the REVEAL trials is complete, reinforcing the company’s data set for advancing to the pivotal Part B trial.
- Ongoing FDA Discussions: Taysha is engaged in productive discussions with the FDA and anticipates providing updates on the pivotal trial design for TSHA-102 in the first half of 2025.
3. Financial Performance Overview
Taysha's financial metrics for the full year 2024 reflect continued investment in research and development:
Key Financial Metrics
- Research and Development Expenses: Increased to $66.0 million from $56.8 million in 2023, primarily due to Good Manufacturing Practices (GMP) batch activities and additional clinical trial activities.
- General and Administrative Expenses: Decreased slightly to $29.0 million from $30.0 million in 2023, attributed mainly to lower issuance costs linked to pre-funded warrants from previous financing.
- Net Loss: The company reported a net loss of $89.3 million, or $0.36 per share, a notable improvement from a net loss of $111.6 million, or $0.96 per share, in the previous year.
Cash Position
As of December 31, 2024, Taysha held $139.0 million in cash and cash equivalents, which management expects will support the company’s operational needs through the fourth quarter of 2026.
4. Future Milestones and Expectations
Looking ahead, Taysha has outlined several anticipated milestones related to the TSHA-102 program:
- Regulatory Update: Expected in the first half of 2025 regarding pivotal trial design.
- Clinical Data Releases: Additional safety and efficacy data from both adolescent/adult and pediatric trials is also anticipated in the same timeframe.
5. About TSHA-102 and Rett Syndrome
TSHA-102 is a self-complementary AAV9 investigational gene transfer therapy designed as a one-time treatment for Rett syndrome, aiming to address the genetic root cause by delivering a functional form of the *MECP2* gene to CNS cells. With no approved disease-modifying therapies currently available, TSHA-102 holds promise for the estimated 15,000 to 20,000 patients affected by this rare neurodevelopmental disorder in the U.S., EU, and U.K.
6. Conclusion
Taysha Gene Therapies is at a pivotal moment in its clinical journey with TSHA-102, making significant strides in both its clinical trials and financial management. The company’s continued focus on advancing innovative gene therapies underscores its commitment to addressing critical unmet medical needs in the CNS space. As Taysha prepares for upcoming regulatory discussions and clinical data releases, the future appears promising for both the company and the patients it aims to serve.
